ArticleHuman molecular genetics2012
The role of genetic breast cancer susceptibility variants as prognostic factors.
Article in Human molecular genetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Impact of germline genetic variation on breast cancer prognosis: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- MAP3K1 rs889312 polymorphism and cancer prognosis: A systematic review and meta-analysis.Cancer reports (Hoboken, N.J.) · 2023Pooled it
- Genome-wide association study of germline variants and breast cancer-specific mortality.British journal of cancer · 2019Pooled it
- Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma.Nature communications · 2016Pooled it
- Association of breast cancer risk loci with breast cancer survival.International journal of cancer · 2015Pooled it
- Common germline polymorphisms associated with breast cancer-specific survival.Breast cancer research : BCR · 2015Pooled it
- A genome wide meta-analysis study for identification of common variation associated with breast cancer prognosis.PloS one · 2014Pooled it
- Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.Scientific reports · 2020Trial
- Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients.BioMed research international · 2014Trial
- Identification of candidate polymorphisms on stress oxidative and DNA damage repair genes related with clinical outcome in breast cancer patients.International journal of molecular sciences · 2012Trial
- MAP3K1: A Multifunctional Kinase at the Crossroads of Cancer Progression and Tumor Suppression.Cells · 2026Review
- Genetic ancestry is related to potential sources of breast cancer health disparities among Colombian women.PloS one · 2024Article
- Article
- Article
- Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer.Geburtshilfe und Frauenheilkunde · 2022Article
- 2q35-rs13387042 variant and the risk of breast cancer: a case-control study.Molecular biology reports · 2022Article
- UACA locus is associated with breast cancer chemoresistance and survival.NPJ breast cancer · 2022Article
- Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.Breast care (Basel, Switzerland) · 2021Article
- Identification and Mechanism of the PD-1/PD-L1 Genomic SignatureFrontiers in genetics · 2021Article
- The association of single nucleotide polymorphisms (SNPs) with breast density and breast cancer survival: the Malmö Diet and Cancer Study.Acta radiologica (Stockholm, Sweden : 1987) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
99 authors.
Funding
Abstract
Recent genome-wide association studies identified 11 single nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk. We investigated these and 62 other SNPs for their prognostic relevance. Confirmed BC risk SNPs rs17468277 (CASP8), rs1982073 (TGFB1), rs2981582 (FGFR2), rs13281615 (8q24), rs3817198 (LSP1), rs889312 (MAP3K1), rs3803662 (TOX3), rs13387042 (2q35), rs4973768 (SLC4A7), rs6504950 (COX11) and rs10941679 (5p12) were genotyped for 25 853 BC patients with the available follow-up; 62 other SNPs, which have been suggested as BC risk SNPs by a GWAS or as candidate SNPs from individual studies, were genotyped for replication purposes in subsets of these patients. Cox proportional hazard models were used to test the association of these SNPs with overall survival (OS) and BC-specific survival (BCS). For the confirmed loci, we performed an accessory analysis of publicly available gene expression data and the prognosis in a different patient group. One of the 11 SNPs, rs3803662 (TOX3) and none of the 62 candidate/GWAS SNPs were associated with OS and/or BCS at P<0.01. The genotypic-specific survival for rs3803662 suggested a recessive mode of action [hazard ratio (HR) of rare homozygous carriers=1.21; 95% CI: 1.09-1.35, P=0.0002 and HR=1.29; 95% CI: 1.12-1.47, P=0.0003 for OS and BCS, respectively]. This association was seen similarly in all analyzed tumor subgroups defined by nodal status, tumor size, grade and estrogen receptor. Breast tumor expression of these genes was not associated with prognosis. With the exception of rs3803662 (TOX3), there was no evidence that any of the SNPs associated with BC susceptibility were associated with the BC survival. Survival may be influenced by a distinct set of germline variants from those influencing susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.